ArticleJournal of medicinal chemistry2026

CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease.

Xiaochen Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.